Preliminary tests on Moderna's Mpox vaccine have shown promising results. The information was published in the journal Cell.

According to a News to the MinuteThe immunizer showed greater efficacy in fighting the disease compared to Jynneoss. During tests, Moderna's vaccine was able to reduce skin lesions and viral replication of the mpox virus in infected animals.

According to the pharmaceutical company, this new vaccine can be used to treat and prevent the disease. Unlike the previous one, this immunizer uses the same technology as the main vaccines against Covid-19, messenger RNA.

Human trials are scheduled for 2025.

(Photo DR)